Anbogen Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, ...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology ...
Taiwan's delegation, led by BPIPO (Biotechnology and Pharmaceutical Industries Promotion Office), organized by the Ministry of Economic Affairs, and...
OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugate...
AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and...
JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, announced the preliminary results of a research collaboration ...
ACRO Biomedical Co., announced that its ABCcolla® Collagen Ophthalmic Matrix has received regulatory approval from Taiwan's&n...
ICP DAS-BMP (Biomedical Polymers), a committed Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is excited to...
-Vertex Pharmaceuticals Incorporated and Zai Lab Limited announced an exclusive collaboration and license agreement for the development a...
Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Medvisis Switze...
Bora Pharmaceuticals Co., Ltd. ("Bora" or "the Company", TWSE: 6472), announced that its Board of Directors has approved the acquisition of US-based ...
Emergent BioSolutions Inc. announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate of B...
-Parse Biosciences, a leading provider of cost-effective and scalable solutions for single-cell sequencing, today announced an agreement with the Taiwane...
Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with c...
© 2025 Biopharma Boardroom. All Rights Reserved.
